ライフサイエンスコーパス: GLP-1

1 GLP-1 decreases Kv1.3 channel contribution to outward cu

2 GLP-1 effects are mediated through binding to the GLP-1

3 GLP-1 induction from engineered mouse cells grafted onto

4 GLP-1 is capable of regulating the blood glucose level b

5 GLP-1 is produced by cells that express proglucagon (GCG

6 GLP-1 neurons may therefore serve as 'satiety sensors' f

7 GLP-1 peptide agonists are efficacious drugs for the tre

8 GLP-1 receptor agonists have a favourable risk-benefit b

9 GLP-1 signalling occurs in the brain; using a newly deve

10 drugs - insulin and glucagon-like peptide 1 (GLP-1) - for treatment of type 2 diabetes.

11 Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in e

12 -4 is a long acting glucagon-like peptide 1 (GLP-1) analogue that is an agonist for the GLP-1 recepto

13 l activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead t

14 53 increased plasma glucagon-like peptide 1 (GLP-1) and insulin levels and improved glucose tolerance

15 Glucagon-like peptide 1 (GLP-1) and serotonin play critical roles in energy balan

16 al incretin hormone glucagon-like peptide 1 (GLP-1) by alpha cells and acts directly on beta cells to

17 osis of the hormone glucagon-like peptide 1 (GLP-1) by the intestinal L cell is essential for the inc

18 Since glucagon-like peptide 1 (GLP-1) exerts neuroprotective effects in the central ner

19 utic engineering of glucagon-like peptide 1 (GLP-1) has enabled development of new medicines to treat

20 Glucagon-like peptide 1 (GLP-1) immunoreactivity of plasma collected immediately

21 Glucagon-like peptide 1 (GLP-1) is a hormone with essential roles in regulating i

22 gut hormone called glucagon-like peptide 1 (GLP-1) is a strong moderator of energy homeostasis and c

23 Glucagon-like peptide 1 (GLP-1) is secreted by intestinal L-cells, and augments g

24 logic properties of glucagon-like peptide 1 (GLP-1) make it a potent candidate drug target in the tre

25 iated the effect of glucagon-like peptide 1 (GLP-1) on glucose-induced insulin secretion, which could

26 The glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) is a key target for type 2 diab

27 of the hypothalamic glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) promotes weight loss and improv

28 Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1-RAs) act on multiple tis

29 tes have shown that glucagon-like peptide 1 (GLP-1) receptor agonists prevent beta-cell loss.

30 )F-DOPA] PET-CT and glucagon-like peptide 1 (GLP-1) receptor imaging), and development of novel medic

31 Glucagon-like peptide 1 (GLP-1) regulates glucose homeostasis through the control

32 those means induce glucagon-like peptide 1 (GLP-1) secretion.

33 the hypothesis that glucagon-like peptide 1 (GLP-1) therapies improve cardiac contractile function at

34 clinically relevant glucagon-like peptide 1 (GLP-1) was functionalized with diflunisal, indomethacin,

35 the degradation of glucagon-like peptide 1 (GLP-1), and has been approved for the treatment of type

36 polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and peptide tyrosine tyrosine (PYY)] were measur

37 ing only), insulin, glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and ghrelin.

38 Glucagon-like peptide 1 (GLP-1), secreted from intestinal L cells, glucose depend

39 the stimulation of glucagon-like peptide 1 (GLP-1), which is known to slow gastric emptying, stimula

40 Glucagon-like Peptide 1 (GLP-1)-expressing neurons in the hindbrain send robust p

41 thereby stimulates glucagon-like peptide 1 (GLP-1)-mediated insulin secretion by upregulating interl

42 resent evidence for glucagon-like peptide 1 (GLP-1)-mediated paraventricular hypothalamic circuit coo

43 d satiating peptide glucagon-like peptide 1 (GLP-1).

44 he incretin hormone glucagon-like peptide 1 (GLP-1).

45 Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor (GLP-1R)

46 PP4) inhibitors and glucagon-like peptide-1 (GLP-1) analogs, are important new classes of therapy for

47 y of semaglutide, a glucagon-like peptide-1 (GLP-1) analogue in clinical development, compared with i

48 Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 development for type 2 diabet

49 Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, concentration

50 of both endogenous glucagon-like peptide-1 (GLP-1) and exogenous GLP-1 receptor (GLP-1R) agonists ar

51 , and the incretins glucagon-like peptide-1 (GLP-1) and GIP (glucose-dependent insulinotropic polypep

52 .05]; and increased glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) compared with all other trea

53 ll derived hormones glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) in vitro from mouse and huma

54 l peptides, such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), from enteroendocrine cells

55 gical properties of glucagon-like peptide-1 (GLP-1) ensure that it is a promising drug candidate for

56 suggests a role for glucagon-like peptide-1 (GLP-1) in modulating stress responses.

57 stinal secretion of glucagon-like peptide-1 (GLP-1) in wild-type, Fxr(-/-), and Tgr5(-/-) mice.

58 nicotine activates glucagon-like peptide-1 (GLP-1) neurons in the nucleus tractus solitarius (NTS).

59 Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R), glucagon (GCG) receptor (GCGR)

60 Exendin-4 (EX-4), a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to reduce food i

61 Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in

62 Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transport

63 Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering

64 Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the

65 take inhibitor, and glucagon-like peptide-1 (GLP-1) receptor agonists.

66 The glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic

67 The glucagon-like peptide-1 (GLP-1) receptors are important biomarkers for imaging pa

68 s while stimulating glucagon-like peptide-1 (GLP-1) secreting enteroendocrine L-cells, we have design

69 Glucagon-like peptide-1 (GLP-1) signaling through the glucagon-like peptide 1 rec

70 ical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years and includes contributio

71 Alhough the glucagon-like peptide-1 (GLP-1) system is critical to energy balance control and

72 abetes therapeutic, glucagon-like peptide-1 (GLP-1), and the target of clinical investigation, gastri

73 recombinant microbial delivery vector for a GLP-1 analogue and assess the efficacy of the therapeuti

74 ucose in Gipr null and Lepr(db/db) mice in a GLP-1 receptor-dependent manner.

75 rk, we show that lipid conjugated forms of a GLP-1/GIP/glucagon hybrid peptides stay in circulation f

76 this model can be effectively treated with a GLP-1 receptor agonist.

77 d the safety and efficacy of the long-acting GLP-1 analogue, liraglutide, in patients with non-alcoho

78 The clinical efficacies of long-acting GLP-1 derivatives strongly support discovery pursuits ai

79 Liraglutide, a long-acting GLP-1 receptor agonist, is approved for treatment of obe

80 that systemic infusion of cocaine activates GLP-1-expressing neurons in the nucleus tractus solitari

81 latory nodes synergistically elevated active GLP-1 to unprecedented concentrations ( approximately 30

82 To study active GLP-1, glucose-dependent insulinotropic polypeptide rece

83 As a regulator of neuronal activity, GLP-1 or its analogue may comprise a new metabolic facto

84 on-like peptide 1 (GLP-1) receptor agonists (GLP-1-RAs) act on multiple tissues, in addition to the p

85 ndings show cardiovascular safety across all GLP-1 receptor agonist cardiovascular outcome trials and

86 nsulin-related side effects reported for all GLP-1 receptor agonists.

87 In vitro, all GLP-1 analogues had subnanomolar GLP-1 receptor potency.

88 y (2.4 +/- 0.2-fold increase, P < 0.01), and GLP-1 peak increased 3.8 +/- 0.6-, 4.7 +/- 0.8-, and 4.4

89 racellular Ca(2+) levels, cAMP activity, and GLP-1 secretion and improved glucose and lipid metabolis

90 tiotemporal glucose and Ca(2+) dynamics, and GLP-1 secretion.

91 0 knockout mice blunted Pcsk1 expression and GLP-1 release from GLUTag cells.

92 Both glucagon and GLP-1 are derived from alternate splicing of a common pr

93 In contrast, glucose- and GLP-1-stimulated insulin secretion was not affected in i

94 esults were similar for DPP-4 inhibitors and GLP-1 analogues.

95 ctreotide formulations, mTOR inhibitors, and GLP-1 receptor antagonists) and surgical therapies (eg,

96 The development of insulin and GLP-1 analogs highlights the broad spectrum of drug deli

97 ovements in delivery methods for insulin and GLP-1 receptor agonists are paving the way towards bette

98 demonstrating glucose-dependent insulin and GLP-1 secretion in vitro.

99 RG in beta and L cells increased insulin and GLP-1 secretion up to 50%.

100 verse events were highest with metformin and GLP-1 receptor agonists.

101 rly beneficial stimulating proliferation and GLP-1 secretion.

102 ce displayed defective insulin secretion and GLP-1 action on islets in vivo and in vitro.

103 y comparable to liraglutide, an antidiabetic GLP-1 analogue that carries a long-chain fatty acid.

104 As GLP-1 mimetics are administered systemically in humans,

105 imilar safety profile to currently available GLP-1 receptor agonists, representing a potential treatm

106 or medullary thyroid cancer reported between GLP-1 receptor agonist treatment and placebo.

107 findings support a circuit whereby brainstem GLP-1 activates PVN signaling to mount an appropriate wh

108 CNS astrocytes in energy balance control by GLP-1 signaling.

109 se lowering by these procedures is driven by GLP-1.

110 ng anatomical evidence of endogenous central GLP-1 in the LDTg.

111 y weight are regulated by endogenous central GLP-1.

112 findings suggest that activation of central GLP-1 receptors may also attenuate cocaine taking.

113 tricle, we highlight a population of central GLP-1 receptors rostral to the hindbrain that are involv

114 uating oral agents that increase circulating GLP-1.

115 ion, the gene encoding PC1/3, which controls GLP-1 production, was decreased in knockout mice.

116 y contribute to the mediation of gut-derived GLP-1's effects on food intake, energy homeostasis, and

117 pharmacokinetic investigations of a divalent GLP-1 analogue demonstrated a promising gain in circulat

118 Importantly, divalent GLP-1 analogues showed efficacy comparable to liraglutid

119 In lean mice, the divalent GLP-1 analogues were superior to monovalent analogues wi

120 short hairpin RNA to chronically knock down GLP-1 receptors (GLP-1R) in rats.

121 esulting in hybrid peptides with potent dual GLP-1/glucagon receptor activity.

122 Both DMG and glutamine alone elicited GLP-1 secretion in GLUTag cells and in vivo, whereas act

123 istration of the plasmid DNA (pDNA) encoding GLP-1 decreased diabetic glucose levels to the normoglyc

124 Similar levels of endogenous GLP-1 occur after gastric bypass surgery, and mechanisti

125 VANs in mediating the effects of endogenous GLP-1 on food intake and glycemia and may promote the fu

126 r-population-mediating effects of endogenous GLP-1 signaling are not fully understood.

127 nous GLP-1R agonists (GLP-1RA) or endogenous GLP-1 on these parameters.

128 istochemical analyses reveal that endogenous GLP-1 axons form close synaptic apposition with NTS astr

129 peptidyl peptidase 4 inhibitors that enhance GLP-1 levels in patients with type 2 diabetes.

130 3 insulinoma cell cAMP assays, BETP enhanced GLP-1(9-36)-NH2-stimulated cAMP signaling.

131 nsufficient to depolarize the cell and evoke GLP-1 secretion in the model, suggesting a crucial role

132 lucagon-like peptide-1 (GLP-1) and exogenous GLP-1 receptor (GLP-1R) agonists are an active area of i

133 Conversely, extended GLP-1 microbe intervention improved glucose-dependent in

134 A time effect was noted for fasting GLP-1, fasting PYY, PYY responses, and hunger-rating res

135 R2.60(190) was predicted to be important for GLP-1- and exendin-4-, but not oxyntomodulin-mediated cA

136 samples were drawn at regular intervals for GLP-1 and PYY.

137 ng, role of GLUT2 and glucose metabolism for GLP-1 secretion via an amplifying pathway that increases

138 tonin as a new critical neural substrate for GLP-1 impact on energy homeostasis and expands the curre

139 of insulin, glucagon, cholecystokinin, GIP, GLP-1, and PYY, and an increase in total energy intake (

140 r both), but neither dose affected glucagon, GLP-1, GIP, cholecystokinin, gastric emptying, or energy

141 ts of glucose, insulin, C-peptide, glucagon, GLP-1, and GIP.

142 load affected insulin, C-peptide, glucagon, GLP-1, or GIP.

143 ulin exocytosis under conditions of glucose, GLP-1, or KCl stimulation through a role in modulating i

144 under the curve for the satiety gut hormone GLP-1 was significantly increased from 10 days postopera

145 ly regulates release of the incretin hormone GLP-1 and hence insulin secretion after a meal.

146 prolong the action of the incretin hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (

147 We investigated how GLP-1 secretion is metabolically coupled in L cells (GLU

148 autoradiography on human tissues with (125)I-GLP-1(7-36)NH2 as a radioligand.

149 reduced glucagon levels, suggesting impaired GLP-1 signaling.

150 In GLP-1 and GIP, a single thioamide near the scissile bond

151 No differences in GLP-1 and PYY concentrations and gallbladder volumes wer

152 he pKa values of all the ionizable groups in GLP-1 suggest it is the protonation/deprotonation of the

153 ere is a highly unusual pH-induced switch in GLP-1 aggregation kinetics.

154 igate the effect of C-terminal truncation in GLP-1 and Ex-4 on the cAMP pathway.

155 agonists for multiple gut hormones including GLP-1, glucagon, and gastric inhibitory peptide.

156 pathways can be engaged to robustly increase GLP-1 without invasive surgical or injection regimens.

157 sought to discover mechanisms that increase GLP-1 pharmacologically.

158 ation phase, LQT2 patients display increased GLP-1, GIP, and insulin secretion and defective glucagon

159 Glucose infusion to the ileum increased GLP-1 and PYY secretion, suppressed aspects of VAS-rated

160 ion of circulating ghrelin levels, increased GLP-1 plasma concentration, and remodeling of gut microb

161 r sitagliptin; these only modestly increased GLP-1 ( approximately 5-30 pmol/L).

162 otes beta-cell function through IL-6-induced GLP-1 production in alpha-cells.

163 strated a 63% reduction in forskolin-induced GLP-1 release in vitro (P < 0.001) and a 23% reduction i

164 of the mechanisms underlying glucose-induced GLP-1 secretion from human small intestine.

165 Furthermore, TGR5-induced GLP-1 release from alpha cells was via an Epac-mediated

166 ugs sitagliptin and exenatide, which inhibit GLP-1 breakdown and stimulate GLP-1 receptors, respectiv

167 e-specific IL-6 signaling induces intestinal GLP-1 release to enhance insulin secretion, thereby coun

168 eptor and injection of fluorescence-labelled GLP-1 analogue exendin-4.

169 ort the crystal structure of the full-length GLP-1 receptor bound to a truncated peptide agonist.

170 ed glucose tolerance and circulating leptin, GLP-1, and insulin levels were reduced.

171 t-friendly alternative to currently marketed GLP-1 injectables and can likely be extended to other pe

172 and developing orally active, small-molecule GLP-1 receptor (GLP-1R) agonists.

173 Moreover, GLP-1 expression is post-transcriptionally modulated by

174 r glycemic control surpassing that of native GLP-1.

175 Treatment with MIA-602 normalized GLP-1 and glucagon to control levels in T1D rats.

176 al mechanisms by which cocaine activates NTS GLP-1-expressing neurons, we microinjected corticosteron

177 gs indicate that increased activation of NTS GLP-1-expressing neurons by corticosterone may represent

178 e show dependence of paraventricular nucleus GLP-1 signaling in the coordination of neuroendocrine, a

179 beta-cell models and blocked the ability of GLP-1 agonists and the depolarizing agent KCl to potenti

180 This might be of relevance for the action of GLP-1 mimetics now widely used in the treatment of diabe

181 ht into the molecular mechanism of action of GLP-1 peptides, here we report the crystal structure of

182 Chemogenetic activation of GLP-1 neurons in NTS similarly decreased nicotine intake

183 Activation of GLP-1 receptors in the MHb-IPN circuit abolished nicotin

184 The advantages of GLP-1 for the avoidance of hypoglycemia and the control

185 achieved by engineering synthetic analogs of GLP-1 or the more stable exogenous GLP-1R agonist exendi

186 sformed to express a long-acting analogue of GLP-1 or the isogenic control microbe which solely harbo

187 Important attributes of GLP-1 action and enteroendocrine science are reviewed, w

188 imental findings establishing the biology of GLP-1 as an insulin-stimulating glucoregulatory hormone.

189 1) to examine the expression and content of GLP-1 receptor (GLP-1R) in human and db/db mice retinas;

190 We quantified the contribution of GLP-1 as a mediator of the therapeutic effects of dipept

191 e of non-viral vector based oral delivery of GLP-1 gene through enterohepatic recycling pathways of b

192 a and may promote the further development of GLP-1-based therapies.

193 No significant effect of GLP-1 receptor agonists was identified on fatal and non-

194 als that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult p

195 amino acid glutamine is a potent elicitor of GLP-1 secretion, the responsible mechanism remains uncle

196 hoton microscopy revealed that exocytosis of GLP-1 is biphasic, with a first peak at 1-6 min and a se

197 Amyloid fibril formation of GLP-1 was monitored using thioflavin T fluorescence as a

198 cal mediator of the energy balance impact of GLP-1 receptor (GLP-1R) activation.

199 altered the serum lipidome, independently of GLP-1 secretion.

200 tor 5 antagonist, which blunts inhibition of GLP-1 release, and agonists for TGR5 and GPR40, which st

201 However, the in vivo half-life of GLP-1 is short because of rapid degradation by dipeptidy

202 y, four trials of cardiovascular outcomes of GLP-1 receptor agonists were identified: ELIXA (lixisena

203 The central portion of GLP-1 appears to be critical for achieving bias toward b

204 peptides combining the N-terminal portion of GLP-1 or Ex-4 and the C-terminal segment of the helix-pr

205 gastrointestinal symptoms and the release of GLP-1 and PYY.

206 ters can induce Ca(2+) influx and release of GLP-1 as a result of electrical activity, while glucose

207 c or regulate propionate-mediated release of GLP-1 from mouse colonic preparations defined this physi

208 mitral cell activity through the release of GLP-1.

209 Given the established role of GLP-1 in promoting beta-cell survival, we hypothesized t

210 ible explanation for this unexpected role of GLP-1/Notch.

211 tcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular

212 hibition in vivo of GDH blocked secretion of GLP-1 in response to DMG.

213 olitarius (NTS), the major central source of GLP-1, with the other nuclei in the midbrain and forebra

214 The poor serum stability of GLP-1 has significantly limited its clinical utility, al

215 Here, we describe that stimulation of GLP-1 afferent fibers within the PVN is sufficient to su

216 tide hormones share the overall structure of GLP-1 and Ex-4, with a C-terminal helical segment and a

217 mic control by increasing concentrations of "GLP-1 equivalents" ( approximately 50 pmol/L).

218 This dampening effect on GLP-1 appears to be mediated by increasing intracellular

219 Glucose also has an effect on GLP-1 secretion downstream of electrical activity.

220 effects of 5 wk of resveratrol treatment on GLP-1 secretion, gastric emptying, and glycemic control

221 th a safety profile similar to that of other GLP-1 receptor agonists.

222 decreased hepatic glucose production, other GLP-1-associated effects were not observed - e.g., activ

223 ests that agonists of glucagon-like peptide (GLP-1) receptor exert neuroprotective and neurorestorati

224 e of the gut hormone, glucagon-like peptide (GLP-1), in deep short axon cells (Cajal cells) of the ol

225 the satiety hormone, glucagon-like peptide (GLP-1), using the enteroendocrine cell line, STC-1.

226 Compared with placebo, GLP-1 receptor agonist treatment showed a significant 10

227 Although plasma GLP-1 levels were elevated in diabetic animals, this was

228 s infusion was sufficient to increase plasma GLP-1 levels.

229 eased serum insulin, serum C-peptide, plasma GLP-1, and plasma GIP responses (P=0.03-0.001) and decre

230 Three months postoperatively, GLP-1 area under the curve was associated with early sat

231 Among them, compound 24 is a potent GLP-1 secretagogue, has low effect on gallbladder volume

232 ll proliferation and all caseins were potent GLP-1 secretagogues (except kappa casein).

233 duced anxiety-like behavior, implicating PVN GLP-1 signaling in behavioral stress reactivity.

234 PVT neurons receive GLP-1 innervation from nucleus tractus solitarius prepro

235 Although the Notch receptor GLP-1 was implicated in both interactions, the molecular

236 xr(-/-) and Tgr5(-/-) mice exhibited reduced GLP-1 secretion, which was stimulated by INT-767 in the

237 Moreover, reduced GLP-1 levels are associated with increased obesity progr

238 ferential effects were attributed to reduced GLP-1 receptor expression in diabetic islets.

239 x(9-39)NH2, were compared with the reference GLP-1 receptor agonist [Nle(14),Lys(40)(Ahx-DOTA-(68)Ga)

240 linagliptin treatment increased the relative GLP-1 vs glucagon production in both non-diabetic and di

241 iated genome editing to controllably release GLP-1 (glucagon-like peptide 1), a critical incretin tha

242 mia-induced PC1 expression thereby releasing GLP-1, which in turn increases beta cell mass and functi

243 dependence prevents hypoglycemia, rendering GLP-1 analogs a useful and safe treatment modality in ty

244 issue specimens, we showed a dose-responsive GLP-1 secretion in the ileum at >/=200 mmol/L glucose.

245 glucagon were engineered into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid pe

246 e peptide-1 (GLP-1) action through selective GLP-1 receptor (GLP-1R) agonism or by prevention of enzy

247 s first applied as drug carrier to stabilize GLP-1 against protease degradation by forming a cavity.

248 which inhibit GLP-1 breakdown and stimulate GLP-1 receptors, respectively, decreased nicotine intake

249 Ca(2+) levels and cAMP activity to stimulate GLP-1 secretion and improve hepatic glucose and lipid me

250 agonists for TGR5 and GPR40, which stimulate GLP-1 secretion, were investigated alone and in combinat

251 AVP stimulated GLP-1 and PYY release from primary cultured murine and h

252 e of SGLT1 in controlling glucose-stimulated GLP-1 release in human ileal L cells.

253 d a 23% reduction in oral glucose-stimulated GLP-1 secretion (P < 0.05) in association with impairmen

254 olon, 300 mmol/L glucose potently stimulated GLP-1 release.

255 vitro, all GLP-1 analogues had subnanomolar GLP-1 receptor potency.

256 When added to metformin and sulfonylurea, GLP-1 receptor agonists were associated with the lowest

257 s contributing to food palatability suppress GLP-1.

258 Short-term GLP-1 microbe intervention in rats reduced serum low-den

259 It is known that GLP-1 secreting cells can sense glucose to promote elect

260 Using optogenetic stimulation, we show that GLP-1 excites medial habenular (MHb) projections to the

261 We also show that GLP-1 receptor (GLP-1R) activation augments excitatory s

262 Immunohistochemical data show that GLP-1-producing neurons in the NTS project to the LDTg,

263 Recent studies suggest that GLP-1-RAs act on liver and adipose tissue to reduce insu

264 These data support that GLP-1 agonism augments cardiac efficiency via attenuatio

265 The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146)

266 The GLP-1 receptor (Glp1r) in mice was knocked down in neuro

267 er, is produced in the DTC and activates the GLP-1/Notch receptor on adjacent germ cells to maintain

268 Although the GLP-1 receptor (GLP-1R) is a validated drug target for d

269 ide in cyclic AMP activation assays, but the GLP-1 thiopeptides have much lower beta-arrestin potency

270 (GLP-1) analogue that is an agonist for the GLP-1 receptor, a G-protein coupled receptor (GPCR).

271 nding of peptide-mediated signaling from the GLP-1 receptor and the key role that the central polar n

272 Interestingly the GLP-1 secretory activity was almost always lost or signi

273 efficacy and safety of co-initiation of the GLP-1 receptor agonist exenatide and the SGLT2 inhibitor

274 Using a targeted knockdown of the GLP-1 receptor in the single-minded 1 neurons, we show d

275 receptors to develop improved models of the GLP-1 receptor that predict additional key molecular int

276 able signaling and secretory capacity of the GLP-1 system, we sought to discover mechanisms that incr

277 EC-1/BECN1/Beclin1 acts independently of the GLP-1/Notch or DAF-7/TGF-beta pathways but together with

278 e insulinoma MIN6B1 cells in response to the GLP-1 analog exendin-4.

279 effects are mediated through binding to the GLP-1 receptor (GLP-1R), a class B G-protein-coupled rec

280 PP-4) inhibition (vildagliptin) by using the GLP-1 receptor antagonist exendin [9-39] in patients wit

281 Cotreatment with the GLP-1 receptor agonist exendin-4 reversed the lysosomal

282 Importantly, treatment with the GLP-1 receptor antagonist exendin 9-39 abolished the obs

283 eutic strategy for type 2 diabetes, with the GLP-1 signaling pathway as a potential focus.

284 ns that were activated by food intake; these GLP-1 fibers formed close appositions to putative GLP-1R

285 Initial tests show that a thioamide GLP-1 analogue is biologically active in rats, with an i

286 ules were able to confer albumin affinity to GLP-1 and indicated that affinity is increased for dival

287 yperglycemia-induced switch from glucagon to GLP-1 synthesis in human and mouse islet alpha cells by

288 and beta cells by switching from glucagon to GLP-1 to restore beta cell mass and function under hyper

289 ucose, glucose tolerance, insulin tolerance, GLP-1 and insulin secretion), and decreased blood lipids

290 iacetyl decreased proglucagon mRNA and total GLP-1 from glucose stimulated STC-1 cells.

291 sting a crucial role for SGLT1 in triggering GLP-1 release in agreement with experimental studies.

292 the ability of exendin-4, a clinically used GLP-1 analog, to reduce body weight in rats, suggesting

293 Using GLP-1 receptor antagonists, we aimed to eliminate the in

294 target for the peptide was determined using GLP-1 receptor binding assays, immunocytochemistry for t

295 Finally, AAV-shRNA-mediated knockdown of VTA GLP-1 receptors was sufficient to augment cocaine self-a

296 -pathway species form under conditions where GLP-1 is most prone to form oligomers.

297 Whether GLP-1 mediates beta-cell survival via the key lysosomal-

298 Here we investigated mechanisms by which GLP-1 and serotonin interact at the level of the central

299 analogs by GDH in the L cell may explain why GLP-1 secretion, but not that of insulin, is activated b

300 Incubation with GLP-1 and the GLP-1R agonist exenatide elicited a cAMP r